Revenue Update on Neurocrine Biosciences(NASDAQ:NBIX)

Neurocrine Biosciences(NASDAQ:NBIX) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Earnings per share were $-0.46. Analysts had estimated an EPS of $-0.49.

In a different note, H.C. Wainwright said it Initiates Coverage on Neurocrine Biosciences, according to a research note issued on Jun 29, 2016. The shares have been rated ‘Buy’ by the firm.

Neurocrine Biosciences (NBIX) made into the market gainers list on Fridays trading session with the shares advancing 0.37% or 0.18 points. Due to strong positive momentum, the stock ended at $48.38, which is also near the day’s high of $48.49. The stock began the session at $47.98 and the volume stood at 4,52,336 shares. The 52-week high of the shares is $58.46 and the 52 week low is $31.25. The company has a current market capitalization of $4,197 M and it has 8,67,51,633 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jun 2, 2016, Malcolm Lloyd-smith (Chief Regulatory Officer) sold 9,000 shares at $50.00 per share price.Also, On Jun 2, 2016, Christopher Flint Obrien (Chief Medical Officer) sold 12,500 shares at $50.00 per share price.On May 26, 2016, Richard F Pops (director) sold 15,000 shares at $46.72 per share price, according to the Form-4 filing with the securities and exchange commission.

Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *